All In Biotech

Drug Trial Radar · NCT04988035

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

Last checked: Nov 20, 2026Latest source record: Jun 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

201

Actual

Start

Aug 3, 2021

Primary completion

Apr 23, 2022

Study completion Apr 23, 2022

Sponsor

Sponsor type
NIH
First posted
Aug 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with COVID-19. BET is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 70 domestic sites and 5 international sites. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively large effects. In order to maintain the double blind, each intervention will have a matched placebo. However, the control arm will be shared between interventions and may include participants receiving the matched placebo for a different intervention. The goal is not to determine clear statistical significance for an intervention, but rather to determine which products have clinical data suggestive of efficacy and should be moved quickly into larger studies. Estimates produced from BET will provide an improved basis for designing the larger trial, in terms of sample size and endpoint selection. Products with little indication of efficacy will be dropped on the basis of interim evaluations. In addition, some interventions may be discontinued on the basis of interim futility or efficacy analyses. One or more interventions may be started at any time. The number of interventions enrolling are programmatic decisions and will be based on the number of sites and the pace of enrollment. At the time of enrollment, subjects will be randomized to receive any one of the active arms they are eligible for or placebo. Approximately 200 (100 treatment and 100 shared placebo) subjects will be assigned to each arm entering the platform and a given site will generally have no more than 3 interventions at once. The BET-C stage will evaluate the combination of remdesivir with danicopan vs remdesivir with a placebo. Subjects will be assessed daily while hospitalized. Once subjects are discharged from the hospital, they will have a study visit at Days 8, 15, 22, 29, and 60 as an outpatient. The Day 8, Day 22 and Day 60 visits do not have laboratory tests or collection of samples and may be conducted by phone. All subjects will undergo a series of efficacy and safety laboratory assessments. Safety laboratory tests and blood (serum, plasma and RNA) research samples on Day 1 (prior to study product administration) and Days 3, 5, 8, and 11 while hospitalized. Blood research samples plus safety laboratory tests will be collected on Day 15 and 29 if the subject attends an in-person visit or is still hospitalized. However, if infection control considerations or other restrictions prevent the subject from returning to the clinic, Day 15 and 29 visits may be conducted by phone and only clinical data will be obtained. The primary objective is to evaluate the clinical efficacy of danicopan relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8.

Conditions

  • COVID-19

Interventions

  • DanicopanDrug

    Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor

  • PlaceboOther

    Danicopan matching placebo tablet

  • RemdesivirDrug

    Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories on Day 8Time frame: Day 8

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine - Infectious Disease

    Birmingham, Alabama

  • Kern Medical Center

    Bakersfield, California

  • UCSF Fresno Center for Medical Education and Research - Clinical Research Center

    Fresno, California

  • University of California Los Angeles Medical Center - Westwood Clinic

    Los Angeles, California

  • Hoag Hospital Newport Beach

    Newport Beach, California

  • Penrose Hospital - Emergency Medicine

    Colorado Springs, Colorado

  • St. Francis Medical Center

    Colorado Springs, Colorado

  • St. Anthony Hospital

    Lakewood, Colorado

  • St. Anthony Hospital North Health Campus

    Westminster, Colorado

  • Nuvance Health Danbury Hospital - Infectious Disease

    Danbury, Connecticut

  • Yale School of Medicine - The Anlyan Center for Medical Research & Education - Immunobiology

    New Haven, Connecticut

  • Nuvance Health - Norwalk Hospital - Asthma Pulmonary and Critical Care Medicine

    Norwalk, Connecticut

  • University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine

    Gainesville, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Carle Foundation Hospital

    Urbana, Illinois

  • Northwestern Medicine - Central DuPage Hospital - Infectious Disease

    Winfield, Illinois

  • Norton Healthcare

    Louisville, Kentucky

  • University of Louisville - Division of Infectious Diseases

    Louisville, Kentucky

  • Brigham and Women's Hospital - Infectious Diseases

    Boston, Massachusetts

  • William Beaumont Hospital - Royal Oak Campus - Infectious Disease

    Royal Oak, Michigan

  • Hennepin Healthcare Research Institute

    Minneapolis, Minnesota

  • Mayo Clinic, Rochester - Infectious Diseases

    Rochester, Minnesota

  • University of Nebraska Medical Center - Infectious Diseases

    Omaha, Nebraska

  • The State University of New York - University at Buffalo - Department of Medicine

    Buffalo, New York

  • Mount Sinai School of Medicine - Medicine - Infectious Diseases

    New York, New York

  • Nuvance Health - Vassar Brothers Medical Center

    Poughkeepsie, New York

  • Stony Brook Medicine - Stony Brook University Hospita

    Stony Brook, New York

  • Jacobi Medical Center

    The Bronx, New York

  • Montefiore Medical Center - Infectious Diseases

    The Bronx, New York

  • Wake Forest Baptist Health - Infectious Diseases

    Winston-Salem, North Carolina

  • St. Charles Health System - St. Charles Bend Hospital

    Bend, Oregon

  • Doylestown Hospital

    Doylestown, Pennsylvania

  • Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases

    Hershey, Pennsylvania

  • Kent County Memorial Hospital

    Warwick, Rhode Island

  • Hendrick Health - Hendrick Medical Center

    Abilene, Texas

  • Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants

    Dallas, Texas

  • University of Utah - Infectious Diseases

    Salt Lake City, Utah

  • West Virginia University - Infectious Diseases Clinic

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.